

Table 2.9. Case-control studies of tamoxifen use and ovarian cancer

Reference, study location and period	Characteristics of cases	Characteristics of controls	Exposure assessment	Exposure categories	No. of cases	Relative risk (95% CI)	Comments
Metcalf et al. (2005), International 1975–2000	491 women with a <i>BRCA1</i> or <i>BRCA2</i> mutation after a primary diagnosis between 1975 and 2000 of breast cancer and followed to 2002	NR	Medical records	Tamoxifen: Any use	NR	1.79 (0.79–4.06)	Multivariate model adjusted for mutation, age, chemotherapy
Swerdlow and Jones (2007), United Kingdom 1983–1996	158 cases of ovarian cancer after breast cancer diagnosed at ages under 55 years	464 controls who had breast cancer at these ages without subsequent ovarian cancer who had not had an oophorectomy	From medical records.	Tamoxifen: Any use	85	0.9 (0.6–1.3)	Registry-based study